{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-007972","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.245253+00:00","generated_at":"2026-05-30T01:27:02.664884+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aethlon Medical reports Q2 net loss $2.8M; enrolls first 2 patients in Hemopurifier cancer trial","bullets":["Net loss narrowed to $2.8M from $3.0M YoY; cash balance $6.9M as of Sep 30, 2024.","Enrolled first two patients in safety/feasibility Hemopurifier trial for solid tumors at Royal Adelaide Hospital.","Two Australian sites open; third site ethics approval pending; India site approved at Medanta Medicity.","James Frakes permanently appointed CEO, previously interim since Nov 2023.","Operating expenses decreased 9% to $2.9M due to cost-cutting and legal fee reductions."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-007972","json":"https://secwatch.observer/filing/0001683168-24-007972.json","markdown":"https://secwatch.observer/filing/0001683168-24-007972.md","text":"https://secwatch.observer/filing/0001683168-24-007972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316824007972/0001683168-24-007972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316824007972/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:27:02.664884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}